- Home
- MNDO vs MURA Comparison
MNDO vs MURA Comparison
Compare MNDO & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNDO
- MURA
- Stock Information
- Founded
- MNDO 1995
- MURA 2013
- Country
- MNDO Israel
- MURA Ireland
- Employees
- MNDO N/A
- MURA N/A
- Industry
- MNDO EDP Services
- MURA
- Sector
- MNDO Technology
- MURA
- Exchange
- MNDO Nasdaq
- MURA Nasdaq
- Market Cap
- MNDO 26.5M
- MURA 30.7M
- IPO Year
- MNDO 2000
- MURA N/A
- Fundamental
- Price
- MNDO $1.33
- MURA $1.59
- Analyst Decision
- MNDO
- MURA Strong Buy
- Analyst Count
- MNDO 0
- MURA 3
- Target Price
- MNDO N/A
- MURA $12.00
- AVG Volume (30 Days)
- MNDO 30.3K
- MURA 206.3K
- Earning Date
- MNDO 08-19-2025
- MURA 08-04-2025
- Dividend Yield
- MNDO 16.54%
- MURA N/A
- EPS Growth
- MNDO N/A
- MURA N/A
- EPS
- MNDO 0.17
- MURA N/A
- Revenue
- MNDO $20,677,000.00
- MURA N/A
- Revenue This Year
- MNDO N/A
- MURA N/A
- Revenue Next Year
- MNDO N/A
- MURA N/A
- P/E Ratio
- MNDO $7.82
- MURA N/A
- Revenue Growth
- MNDO N/A
- MURA N/A
- 52 Week Low
- MNDO $1.29
- MURA $0.95
- 52 Week High
- MNDO $2.13
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- MNDO 37.92
- MURA 15.71
- Support Level
- MNDO $1.29
- MURA $1.53
- Resistance Level
- MNDO $1.35
- MURA $2.40
- Average True Range (ATR)
- MNDO 0.04
- MURA 0.15
- MACD
- MNDO -0.01
- MURA -0.09
- Stochastic Oscillator
- MNDO 19.05
- MURA 6.04
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.